| Peer-Reviewed

A Comprehensive Literature Review on the Pandemic Coronavirus Disease 2019 (COVID-19): Bangladesh Is Fighting Against It

Received: 29 May 2020     Accepted: 10 June 2020     Published: 6 July 2020
Views:       Downloads:
Abstract

A large number of patient developed pneumonia of unknown cause in the capital city Wuhan of Hubei province in China during the month of Dec 2019, with clinical presentations greatly resembling viral pneumonia while some rapidly progressed to severe illness and fatal outcome. International Committee on Taxonomy of Viruses (ICTV) named the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and WHO officially named the disease COVID-19. World Health Organization (WHO) on January 30 declared the outbreak as a public health emergency of international concern due to rapid global spread. On 11 February 2020, WHO announced that "COVID-19" (meaning coronavirus disease-2019) will be the official name of the disease. This report reviews the genetic structure, infection source, transmission route, pathogenesis, clinical characteristics, and treatment and prevention of the SARS-CoV-2, so that it can provide references for follow-up research, prevention and treatment, and may help readers to have the latest understanding of this new infectious disease. Information have been gathered mainly from relevant researches and papers that were published recently. For this narrative review, more than 49 relevant scientific articles and reports were considered from various databases (e.g., Google Scholar, PubMed and Science Direct) using keywords such as SARS-CoV-2; COVID-19; corona virus; pneumonia; respiratory infection. The results from this review show that the situation is rapidly evolving, as human-to-human transmission is occurring, and the number of new cases and mortalities is increasing by the day and on a global level. There is still ambiguity about mutation risks and how the virus spreads as the source was not yet identified. Major gaps in knowledge about the origin of the virus, epidemiology and transmission impose a great challenge, which emphasizes the need for further studies in the future. There are neither vaccines nor effective treatments for the disease caused by the virus, but efforts are typically confined to symptomatic and supportive management. Antiviral and corticosteroids were used in severe illness but had no effective outcome.

Published in American Journal of Biomedical and Life Sciences (Volume 8, Issue 4)
DOI 10.11648/j.ajbls.20200804.13
Page(s) 76-82
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2020. Published by Science Publishing Group

Keywords

SARS-CoV-2, COVID-19, Corona Virus, Pneumonia, Respiratory Infection

References
[1] Regan H, Renton A, John T (2020) Global death toll rises to 2, 458 as Hubei province in China reports more deaths. CNN.
[2] Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Tan, W. (2020). Genomic characterization and epidemiology of 2019 novel corona virus: implications for virus origins and receptor binding. Lancet (London, England), 6736 (20), 1–10.
[3] World Health Organization. Corona virus disease 2019 (COVID-19) Situation Report –51. Data as reported by national authorities by 10 AM CET 11 March 2020.
[4] Gorbalenya, Alexander E. Severe acute respiratory syndrome-related corona virus –The species and its viruses, a statement of the Coronavirus Study Group. Posted on 11 February 2020.
[5] Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of corona viruses. Trends Microbiol. 2016; 24 (6): 490-502.
[6] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel corona virus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020; 395 (10223): 507-513.
[7] Cui J, Li F, Shi ZL. Origin and evolution of pathogenic corona viruses. Nat Rev Microbial. 2019; 17: 181-192.
[8] Zhong NS, Zheng BJ, Li YM, Poon, Xie ZH, Chan KH, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet. 2003; 362 (9393): 1353-1358.
[9] Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348: 1953-1966.
[10] Weiss SR, Leibowitz JL. Corona virus pathogenesis. Adv Virus Res. 2011; 81: 85-164.
[11] Zaki, A. M., Van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012). Isolation of a novel corona virus from a man with pneumonia in Saudi Arabia. New England Journal of Medicine.
[12] Wang J, Zhao S, Liu M, Zhao Z, Xu Y, Wang P, et al. ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism. 2020: 2020.02.05.20020545.
[13] Xiao F, Tang M, Zheng X, Li C, He J, Hong Z, et al. Evidence for gastrointestinal infection of SARS-CoV-2. medRxiv. 2020: 2020.02.17.20023721.
[14] Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. Journal of medical virology. 2020.
[15] Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet. 2020.
[16] Wan Y, Jian Shang, Rachel Graham, Ralph S Baric, Fang Li (2020) Receptor recognition by a novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virol.
[17] Lu R, Xiang Zhao, Juan Li, Peihua Niu, Bo Yang, et al. (2020) Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet 395 (10224): 565-574.
[18] Hoffmann M, Hannah Kleine Weber, Nadine Krüger, Marcel Müller, Christian Drosten, et al. (2020) The novel coronavirus 2019 (2019- nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv.
[19] Wang D, Bo Hu, Chang Hu, et al. (2020) Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA.
[20] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical feature of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497-506. Published online on 24 Jan 2020.
[21] Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity. Published online on 26 Feb, 2020.
[22] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. Published online on 07 Feb, 2020.
[23] Guan WJ, Ni ZY, Hu Y, et al.: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020, 10.1056/NEJMoa2002032.
[24] Wu Z, McGoogan JM: Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020, 10.1001/jama.2020.2648.
[25] World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance; 28 Jan, 2020.
[26] Chen, Z. M.; Fu, J. F.; Shu, Q.; Chen, Y. H.; Hua, C. Z.; Li, F. B.; Lin, R.; Tang, L. F.; Wang, T. L.; Wang, W.; et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J. Pediatr. 2020. [CrossRef].
[27] Zhang, W.; Du, R.-H.; Li, B.; Zheng, X.-S.; Yang, X.-L.; Hu, B.; Wang, Y.-Y.; Xiao, G.-F.; Yan, B.; Shi, Z.-L. Molecular and serological investigation of 2019-nCoV infected patients: Implication of multiple shedding routes. Emerg. Microbes Infect. 2020, 9, 386–389. [CrossRef] [PubMed].
[28] Shirato, K.; Nao, N.; Katano, H.; Takayama, I.; Saito, S.; Kato, F.; Katoh, H.; Sakata, M.; Nakatsu, Y.; Mori, Y.; et al. Development of genetic diagnostic methods for novel coronavirus 2019 (nCoV-2019) in Japan. Jpn. J. Infect. Dis. 2020, in press. [CrossRef] [PubMed].
[29] Corman, V. M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D. K. W.; Bleicker, T.; Brunink, S.; Schneider, J.; Schmidt, M. L.; et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro. Surveill. 2020, 25, 2000045. [CrossRef] [PubMed].
[30] Wei-Jie G, Zheng-Yi N, Yu Hu, Wen-Hua L, Chun-Quan O, Jian-Xing H, et al. Clinical characteristics of coronavirus disease 2019 in China. NEJM. Published online on 28 Feb, 2020.
[31] De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: Recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14: 523-534.
[32] Lu H. Drug treatment options for the 2019- new coronavirus (2019-nCoV). Biosci Trends. Published online on 28 Jan 2020.
[33] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 4 Feb, 2020.
[34] Zhijian X, Cheng P, Yulong S, Zhengdan Z, Kaijie M, Xiaoyu Wang, et al. Nelfinavir was predicted to be a potential inhibitor of 2019 nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. Posted on: 28 Jan, 2020.
[35] World Health Organization, 2020. Coronavirus disease (COVID-19) advice for the public. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advicefor-public/when-and-how-to-use-masks.
[36] "Bangladesh confirms its first three cases of coronavirus". Reuters. 8 March 2020. Archived from the original on 27 March 2020. Retrieved 27 March 2020.
[37] 20-fold rise in Covid-19 cases in Bangladesh since April 1, Dhaka Tribune, 14 April 2020.
[38] Mint Covid Tracker: India’s corona trajectory has tapered this week but still remains steeper than Asian peers, livemint, 11 April 2020.
[39] Research (IEDCR), Institute of Epidemiology, Disease Control and. "Corona info". corona.gov.bd. Retrieved 3 May 2020.
[40] "Screening starts at Dhaka, Ctg airports". Screening starts at Dhaka, Ctg airports | theindependentbd.com. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
[41] "Virus prompts temperature checks, extra cleaning at airports". ABC News. Retrieved 28 March 2020.
[42] "Government sends plane today to fly back citizens". New Age. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
[43] "312 Bangladeshis quarantined in Dhaka after arriving from Wuhan". New Age. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
[44] "Govt brings 361 back from Wuhan early Saturday". New Age. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
[45] "Expats asked to call IEDCR if in difficulties". New Age. Retrieved 28 March 2020.
[46] "23 Bangladeshis flown to Delhi from Wuhan". New Age. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
[47] "IEDCR asks returnees from virus-affected countries to avoid public transport". The Daily Star. 8 March 2020. Archived from the original on 9 April 2020. Retrieved 8 April 2020.
[48] Mamun Abdullah, Number of ICU beds insufficient to combat Covid-19 pandemic, Dhaka Tribune, 21 March 2020.
[49] Bangladesh may suffer setback in its fight against corona virus for shortage of life-saving ventilators: Physicians, UNB (United News of Bangladesh), 10 April 2020.
Cite This Article
  • APA Style

    Umme Shahera, Nahida Sultana, Mahbuba Sharmin, Jayanta Malakar, Muhammad Rashedul Islam, et al. (2020). A Comprehensive Literature Review on the Pandemic Coronavirus Disease 2019 (COVID-19): Bangladesh Is Fighting Against It. American Journal of Biomedical and Life Sciences, 8(4), 76-82. https://doi.org/10.11648/j.ajbls.20200804.13

    Copy | Download

    ACS Style

    Umme Shahera; Nahida Sultana; Mahbuba Sharmin; Jayanta Malakar; Muhammad Rashedul Islam, et al. A Comprehensive Literature Review on the Pandemic Coronavirus Disease 2019 (COVID-19): Bangladesh Is Fighting Against It. Am. J. Biomed. Life Sci. 2020, 8(4), 76-82. doi: 10.11648/j.ajbls.20200804.13

    Copy | Download

    AMA Style

    Umme Shahera, Nahida Sultana, Mahbuba Sharmin, Jayanta Malakar, Muhammad Rashedul Islam, et al. A Comprehensive Literature Review on the Pandemic Coronavirus Disease 2019 (COVID-19): Bangladesh Is Fighting Against It. Am J Biomed Life Sci. 2020;8(4):76-82. doi: 10.11648/j.ajbls.20200804.13

    Copy | Download

  • @article{10.11648/j.ajbls.20200804.13,
      author = {Umme Shahera and Nahida Sultana and Mahbuba Sharmin and Jayanta Malakar and Muhammad Rashedul Islam and Kazi Mohammed Zafrul Haq},
      title = {A Comprehensive Literature Review on the Pandemic Coronavirus Disease 2019 (COVID-19): Bangladesh Is Fighting Against It},
      journal = {American Journal of Biomedical and Life Sciences},
      volume = {8},
      number = {4},
      pages = {76-82},
      doi = {10.11648/j.ajbls.20200804.13},
      url = {https://doi.org/10.11648/j.ajbls.20200804.13},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20200804.13},
      abstract = {A large number of patient developed pneumonia of unknown cause in the capital city Wuhan of Hubei province in China during the month of Dec 2019, with clinical presentations greatly resembling viral pneumonia while some rapidly progressed to severe illness and fatal outcome. International Committee on Taxonomy of Viruses (ICTV) named the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and WHO officially named the disease COVID-19. World Health Organization (WHO) on January 30 declared the outbreak as a public health emergency of international concern due to rapid global spread. On 11 February 2020, WHO announced that "COVID-19" (meaning coronavirus disease-2019) will be the official name of the disease. This report reviews the genetic structure, infection source, transmission route, pathogenesis, clinical characteristics, and treatment and prevention of the SARS-CoV-2, so that it can provide references for follow-up research, prevention and treatment, and may help readers to have the latest understanding of this new infectious disease. Information have been gathered mainly from relevant researches and papers that were published recently. For this narrative review, more than 49 relevant scientific articles and reports were considered from various databases (e.g., Google Scholar, PubMed and Science Direct) using keywords such as SARS-CoV-2; COVID-19; corona virus; pneumonia; respiratory infection. The results from this review show that the situation is rapidly evolving, as human-to-human transmission is occurring, and the number of new cases and mortalities is increasing by the day and on a global level. There is still ambiguity about mutation risks and how the virus spreads as the source was not yet identified. Major gaps in knowledge about the origin of the virus, epidemiology and transmission impose a great challenge, which emphasizes the need for further studies in the future. There are neither vaccines nor effective treatments for the disease caused by the virus, but efforts are typically confined to symptomatic and supportive management. Antiviral and corticosteroids were used in severe illness but had no effective outcome.},
     year = {2020}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - A Comprehensive Literature Review on the Pandemic Coronavirus Disease 2019 (COVID-19): Bangladesh Is Fighting Against It
    AU  - Umme Shahera
    AU  - Nahida Sultana
    AU  - Mahbuba Sharmin
    AU  - Jayanta Malakar
    AU  - Muhammad Rashedul Islam
    AU  - Kazi Mohammed Zafrul Haq
    Y1  - 2020/07/06
    PY  - 2020
    N1  - https://doi.org/10.11648/j.ajbls.20200804.13
    DO  - 10.11648/j.ajbls.20200804.13
    T2  - American Journal of Biomedical and Life Sciences
    JF  - American Journal of Biomedical and Life Sciences
    JO  - American Journal of Biomedical and Life Sciences
    SP  - 76
    EP  - 82
    PB  - Science Publishing Group
    SN  - 2330-880X
    UR  - https://doi.org/10.11648/j.ajbls.20200804.13
    AB  - A large number of patient developed pneumonia of unknown cause in the capital city Wuhan of Hubei province in China during the month of Dec 2019, with clinical presentations greatly resembling viral pneumonia while some rapidly progressed to severe illness and fatal outcome. International Committee on Taxonomy of Viruses (ICTV) named the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and WHO officially named the disease COVID-19. World Health Organization (WHO) on January 30 declared the outbreak as a public health emergency of international concern due to rapid global spread. On 11 February 2020, WHO announced that "COVID-19" (meaning coronavirus disease-2019) will be the official name of the disease. This report reviews the genetic structure, infection source, transmission route, pathogenesis, clinical characteristics, and treatment and prevention of the SARS-CoV-2, so that it can provide references for follow-up research, prevention and treatment, and may help readers to have the latest understanding of this new infectious disease. Information have been gathered mainly from relevant researches and papers that were published recently. For this narrative review, more than 49 relevant scientific articles and reports were considered from various databases (e.g., Google Scholar, PubMed and Science Direct) using keywords such as SARS-CoV-2; COVID-19; corona virus; pneumonia; respiratory infection. The results from this review show that the situation is rapidly evolving, as human-to-human transmission is occurring, and the number of new cases and mortalities is increasing by the day and on a global level. There is still ambiguity about mutation risks and how the virus spreads as the source was not yet identified. Major gaps in knowledge about the origin of the virus, epidemiology and transmission impose a great challenge, which emphasizes the need for further studies in the future. There are neither vaccines nor effective treatments for the disease caused by the virus, but efforts are typically confined to symptomatic and supportive management. Antiviral and corticosteroids were used in severe illness but had no effective outcome.
    VL  - 8
    IS  - 4
    ER  - 

    Copy | Download

Author Information
  • Department of Virology, Bangabandhu sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh

  • Department of Virology, Bangabandhu sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh

  • Department of Hematology, Bangabandhu sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh

  • Department of Cardiology, Dhaka Medical College Hospital (DMCH), Dhaka, Bangladesh

  • Director General of Medical Education, Dhaka, Bangladesh

  • National Institute of Cardiovascular Diseases and Hospital (NICVD), Dhaka, Bangladesh

  • Sections